TAKEDA PHARM SP ADR (TAK)
$15.17
0.00 (0.00%)
TAK Stock Quote Delayed 30 Minutes
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024
Takeda Pharmaceutical just reported results for the first quarter of 2024.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$15.00
Market Cap
24.01B
PE Ratio
0.17
EPS
91.16
Volume (Avg. Vol.)
1.57M
Day's Range
$15.08 - $15.22
52-Week Range
$12.29 - $15.22
Dividend & Yield
$0.62 (4.08%)
TAK Stock Predictions, Articles, and TAKEDA PHARM SP ADR News
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023
Takeda Pharmaceutical just reported results for the fourth quarter of 2023.
What I Changed About My Income Investing Strategy
If you’re looking to catch up on lost profits, secure your retirement, and even splurge for that new car, check out my investment strategy.
Blackstone to Buy Takeda Pharmaceutical Consumer Unit
Blackstone (BX) will be acquiring Takeda Consumer Healthcare, which is the consumer division of Takeda Pharmaceutical (TAK).
The 7 Most Undervalued Stocks In Larry Robbins’ Portfolio
Larry Robbins is a well-known GARP investor. Here are some of his hedge fund's -- Glenview Capital Management -- most undervalued stocks.
Shire (SHPG) a Sell on Sagging Quant Score
Currently, Shire plc (NASDAQ:SHPG) has a Sell using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. SHPG has maintained this ranking for 11 months.
Lousy Quant Score Make Shire (SHPG) a Sell
Shire plc (NASDAQ:SHPG) is a constituent of the 350 company Biotechnology GICS industry group, which is part of the 782 company GICS Health Care sector. SHPG's market value is $44.8 billion which places it in the top 10% of its industry group. The current Portfolio Grader ranking for SHPG puts it 233 among the 350 companies in this industry group, which is a below-average position; in the third quartile of the sector with a ranking of 538 among the 782 companies in the sector, and number 3,229 in the nearly 5,000 company Portfolio Grader universe.
Shire (SHPG) a Sell on Flopping Industry Group Rank
With a $44.7 billion market value, Shire plc (NASDAQ:SHPG) ranks in the top decile in its industry group, Biotechnology, and in the top 10% of its sector group, Health Care, in market value. From the vantage point of investment attractiveness, the ranking for SHPG by Portfolio Grader places it 216 among the 349 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 521 among the 781 companies in the sector, and number 3,243 in the nearly 5,000 company Portfolio Grader universe.
Earnings Growth Make Shire (SHPG) a Sell
Currently, Shire plc (NASDAQ:SHPG) has a Sell using Louis Navellier's investing system and his Portfolio Grader stock evaluator. SHPG has maintained this ranking for 11 months.
Analytics for Industry Group Rank Make Shire (SHPG) a Sell
Currently, Shire plc (NASDAQ:SHPG) has a Sell using Louis Navellier's approach to investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking SHPG has had from Portfolio Grader for 11 months.
